- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Interventions
- muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation
- Biological · Drug · Genetic + 3 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 45 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 20,612
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis
- Interventions
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®), Placebo
- Drug
- Lead sponsor
- Synthon BV
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 794 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Irvine, California • Port Charlotte, Florida • Sunrise, Florida + 4 more
- Conditions
- Graft Versus Host Disease
- Interventions
- LDE225
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Hepatitis C, Human Immunodeficiency Virus
- Interventions
- Not listed
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia
- Interventions
- curcumin, cholecalciferol, laboratory biomarker analysis, pharmacological study
- Drug · Dietary Supplement · Other
- Lead sponsor
- Paolo Caimi, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Acute Lymphocytic Leukemia
- Interventions
- Decitabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Asthma
- Interventions
- Mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- San Diego, California • Oklahoma City, Oklahoma • Medford, Oregon + 1 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Computerized patient decision-aid, Usual care (lupus pamphlet)
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Human Immunodeficiency Virus, Hepatitis C, Alcohol Abuse
- Interventions
- Computer-based alcohol reduction intervention, Brief clinician-delivered MET, Standard of care
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 21 Years to 45 Years · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Survivorship, Quality of Life, Cognitive Deficits, Mild
- Interventions
- transcranial direct current stimulation (tDCS), Sham tDCS
- Device
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 50 Years to 85 Years · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Lymphoma
- Interventions
- RFT5-dgA immunotoxin, fluorescence activated cell sorting, immunohistochemistry staining method
- Biological · Other
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
- Device · Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 10 Years to 35 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Stanford, California • Charlottesville, Virginia
- Conditions
- Asthma
- Interventions
- AMAZE™ Disease Management Platform
- Device
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Austin, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Abatacept, Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD), Anti-Tumor Necrosing Factor (TNF) Therapy
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 114
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 111 more
- Conditions
- Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
- Interventions
- Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
- Drug · Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Multiple Myeloma
- Interventions
- BT062
- Drug
- Lead sponsor
- Biotest Pharmaceuticals Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Buffalo, New York + 1 more
- Conditions
- Thyroid Cancer, Graves Disease
- Interventions
- Cervical Collar Therapy Indicator (COTI)
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
- Interventions
- FT-1101, Azacitidine
- Drug
- Lead sponsor
- Forma Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more
- Conditions
- CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- Subcutaneous Blinatumomab
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Graft-Versus-Host Disease
- Interventions
- Prochymal®
- Drug
- Lead sponsor
- Mesoblast, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- U.S. locations
- 3
- States / cities
- Beech Grove, Indiana • Boston, Massachusetts • New York, New York
- Conditions
- Asthma
- Interventions
- albuterol sulfate inhalation aerosol
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- Up to 23 Months
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 27
- States / cities
- Hoover, Alabama • Fort Mohave, Arizona • Jonesboro, Arkansas + 24 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Multiple Myeloma, Breast Cancer
- Interventions
- Zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 7
- States / cities
- West Hollywood, California • Greenwood Village, Colorado • Norwalk, Connecticut + 4 more
- Conditions
- Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)
- Interventions
- Benralizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio